## 3 Results
Genes significantly upregulated in treated cells with respect to the control were CDH1 (E-cadherin), belonging to cell adhesion genes, and MMP24 and MMP8, involved in extracellular matrix deposition. The CDH1 (E-cadherin) levels measured by enzyme linked immunoassay (ELISA) after nifedipine treatment showed an increase of CDH1 levels (5.34-fold \(\pm\) 0.19) in treated \begin{table}
\begin{tabular}{c c c c} \hline \hline
**Gene** & **Fold Change** & **SD** & **Gene Function** \\ \hline MMP2 & 0.73 & 0.10 & Extracellular Matrix Protease \\ \hline MMP3 & 0.90 & 0.08 & Extracellular Matrix Protease \\ \hline MMP7 & 1.03 & 0.42 & Extracellular Matrix Protease \\ \hline MMP8 & **3.98** & 1.47 & Extracellular Matrix Protease \\ \hline MMP9 & 1.04 & 0.35 & Extracellular Matrix Protease \\ \hline MMP10 & 1.24 & 0.05 & Extracellular Matrix Protease \\ \hline MMP11 & **0.14** & 0.05 & Extracellular Matrix Protease \\ \hline MMP12 & 1.20 & 0.13 & Extracellular Matrix Protease \\ \hline MMP13 & 1.14 & 0.19 & Extracellular Matrix Protease \\ \hline MMP14 & 0.96 & 0.07 & Extracellular Matrix Protease \\ \hline MMP15 & 1.90 & 0.08 & Extracellular Matrix Protease \\ \hline MMP16 & **0.38** & 0.04 & Extracellular Matrix Protease \\ \hline MMP24 & **9.68** & 1.05 & Extracellular Matrix Protease \\ \hline MMP26 & **0.31** & 0.01 & Extracellular Matrix Protease \\ \hline TGFB1 & 0.88 & 0.14 & Transforming growth factor \(\beta\) Signaling \\ \hline TGFB2 & 1.20 & 0.12 & Transforming growth factor \(\beta\) Signaling \\ \hline TGFB3 & 0.62 & 0.02 & Transforming growth factor \(\beta\) Signaling \\ \hline TIMP1 & 0.76 & 0.11 & Extracellular Matrix Protease Inhibitor \\ \hline VCAN & 0.75 & 0.03 & Cell Adhesion Molecule \\ \hline RPL13 & 1.00 & 0.00 & Housekeeping gene \\ \hline \hline \end{tabular}
\end{table} 
Table 1: _Cont._ \begin{table}
\begin{tabular}{c c c c} \hline \hline
**Gene** & **Fold Change** & **SD** & **Gene Function** \\ \hline CDH1 & 5.62 & 2.06 & Cell-Cell Adhesion \\ \hline ITGA6 & 0.41 & 0.04 & Transmembrane Receptor \\ \hline ITGB4 & 0.23 & 0.03 & Transmembrane Receptor \\ \hline LAMA1 & 0.45 & 0.04 & Basement Membrane Constituent \\ \hline LAMB1 & 0.39 & 0.02 & Basement Membrane Constituent \\ \hline MMP8 & 3.98 & 1.47 & Extracellular Matrix Protease \\ \hline MMP11 & 0.14 & 0.05 & Extracellular Matrix Protease \\ \hline MMP16 & 0.38 & 0.04 & Extracellular Matrix Protease \\ \hline MMP24 & 9.68 & 1.05 & Extracellular Matrix Protease \\ \hline MMP26 & 0.31 & 0.01 & Extracellular Matrix Protease \\ \hline \hline \end{tabular}
\end{table} 
Table 2: Significant gene expression levels after 24 h treatment with nifedipine, as compared with untreated cells (\(n\) = 3). fibroblasts vs. untreated control, confirming the gene expression results obtained by real-time PCR. Among the significant downregulated genes induced by the treatment, there were transmembrane receptor ITGA6 and ITGB4, the basement membrane constituent LAMA1 and LAMB1, and the extracellular matrix protease MMP11, MMP16, and MMP26. Figure 2 shows the gene expression profile of the significant deregulated genes belonging to the \"Extracellular Matrix and Adhesion Molecules\" pathway.